logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Court Upholds Validity of Amgen's Claims Regarding Enbrel

Press Release Amgen Wins Patent Case On Enbrel® (etanercept) Court Upholds Validity of Patent Claims Directed to Enbrel Preliminary Injunction to Remain in Place THOUSAND OAKS, Calif., Aug. 9, 2019 , /PRNewswire/ --  Amgen ( AMGN ) today announced that the U.S. District...

Read More

August 9, 2019

0

A Press Release About Regeneron Product REGN-EB3 Showing Superiority in Preventing Ebola Deaths

Palm Ebola Clinical Trial Stopped Early as Regeneron Product REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths TARRYTOWN, N.Y., Aug. 12, 2019,/PRNewswire/ --  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that the Company was informed by study...

Read More

August 13, 2019

0

Moderna's Investigational Zika Vaccine Is Granted FDA Fast Track Designation

From Moderna  From the press release we learned that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation for Moderna   ( MRNA ) investigational Zika vaccine (mRNA-1893) currently being evaluated in a Phase 1...

Read More

August 20, 2019

0

Forty Seven Continues to Outperform

Forty Seven On December 21, 2018 Prohost picked Forty Seven ( FTSV ) at $16.95 adding it to its Portfolio of biotech firms with solid scientific and non-scientific fundamentals. Forty Seven develops novel checkpoint therapies to activate macrophages in the...

Read More

January 17, 2020

0

Compugen

Time to Remember Compugen The time has ripened for our readers and biotech investors to remember what we posted in the past years about Compugen ( CGEN ) . The importance of the reminder is that the firm has taken...

Read More

January 30, 2020

0

Vertex Beats Expectations in 2019 and Promises a Bright Future

Vertex Beats Expectations in 2019 Vertex ( VRTX ) reported fourth-quarter and full-year 2019 financial results yesterday. The results beat analysts’ expectations about the last quarter and the whole year 2019. In the same report the firm’s full-year financial guidance...

Read More

January 31, 2020

0

Gilead Stock Is Up 4%. See Also: Who Is Developing Prophylactic Vaccines for Coronavirus and Nektar's News That Moved the Stock Up Over 8%.

Gilead Stock Is UP Gilead Sciences' ( GILD ) provided its antiviral experimental drug remdesivir to physicians for a small number of patients infected with the 2019 novel coronavirus (2019-nCoV ) as a possible emergency savior. Gilead might have also...

Read More

February 3, 2020

0

Exelixis Has Good News for Metastatic Castration-Resistant Prostate Cancer

Exelixis Announced Results from its CABOMETYX® Combination with Roche's TECENTRIQ® News announced by Exelixis ( EXEL ) about encouraging results from the combination of its product cabozantinib ( CABOMETYX® ) with Roche’s product atezolizumab ( TECENTRIQ® ) on metastatic castration-resistant...

Read More

February 11, 2020

0

COVID-19 and the Stock Market

COVID-19 and the Stock Market The coronavirus that causes COVID-19  is the topic that swallowed all other topics this week. The virus is spreading to many countries around the world. Some media interpreted the CDC's warnings as being in direct...

Read More

February 27, 2020

0

Results From Phase I/IIa Trial of RegenxBio Gene Therapy Product RGX-314

RegenxBio Interim Data from Phase I/IIa Trial of RGX-314 for Wet AMD RegenxBio ( RGNX ) announced interim data from the ongoing Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration ( wet AMD ). Here...

Read More

October 14, 2019

0

  • Previous
  • 1
  • 2
  • 3
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy